366
Views
0
CrossRef citations to date
0
Altmetric
Systematic review

Cost-effectiveness of stereotactic body radiotherapy in the treatment of non–small-cell lung cancer (NSCLC): a systematic review

, , , , &
Pages 723-734 | Received 21 Apr 2021, Accepted 03 Mar 2022, Published online: 10 Mar 2022
 

ABSTRACT

Objectives

This study aims to systematically review the studies on the cost-effectiveness of stereotactic body radiotherapy (SBRT) in the treatment of non–small-cell lung cancer (NSCLC).

Methods

A systematic literature search was performed in databases from 2000 through April 2021. The search terms included ‘economics,’ ‘cost,’ ‘cost effectiveness,’ ‘SBRT,’ and all names for NSCLC. Two reviewers independently screened the titles, abstracts and full texts to determine the studies for the final sample. The quality of the included studies was assessed using the Quality of Health Economic Studies checklist.

Results

Eleven studies were identified and included in our final review. SBRT was reported to be a cost-effective (5 of 5) option compared to conventional radiotherapy, radiofrequency ablation, and best supportive care for medically inoperable, early-stage NSCLC. However, the identified studies revealed that no single treatment was found to be more cost-effective than others between SBRT and surgical interventions. The key drivers of this cost-effectiveness were the cost of the treatment, utility value, and the rate of surgical mortality.

Conclusions

SBRT may be considered a more cost-effective strategy for medically inoperable, early-stage NSCLC. Considering the limited studies available, more related research should be conducted to further validate these results.

Declaration of interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

Conception and design: H Wang, C Jin, S Hu. Data acquisition: H Sun, H Wang. Analysis and interpretation of data: H Sun, H Wang. Drafting, revision of the manuscript: H Sun, Y Chen, H Wang. All authors agreed on the final version of the manuscript to be published.

Additional information

Funding

This study was sponsored by Varian Medical Systems, China.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.